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In breast cancer, the presence of Foxp3 (Tregs) [1] within
the tumor milieu has been a matter of debate. Some
studies have determined that infiltration of Tregs was
associated with poor survival, while others revealed no
impact on survival, however this depends on their type,
type of cells expressing Foxp3 and the density of the Tregs
population [2].
The goal of our study was to quantify Foxp3 in breast
cancer patients from Qatar and correlate with their
survival.
Methodology
Expression of FoxP3 was studied in 132 FFPE samples
with known clinico-pathological data by immunohisto-
chemistry technique and quantified by modified H-score
system by pathologist. Results were analyzed via SPSS.
Results
Analysis was carried for 132 patients. Age at time of
diagnosis was 49 ±10.4 years. 76.2% of the patients showed
positive expression of FoxP3. FoxP3 expression was not
correlated with patient age or hormone receptors.
Expression of Foxp3 positively correlate with better patient
survival when compared to negative expression (94.1, 95%
CI 85.6 - 102.6 versus 83.6, 95% CI 71.8 - 95.5, p 0.60).
Conclusion
FoxP3 is expressed on lymphocytes that are present in
the tumor microenvironment regardless of breast cancer
subtypes. Foxp3 is correlated with better survival.
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